Home › Funds › SATURNA CAPITAL CORP › ABT
SATURNA CAPITAL CORP position in ABT
ABBOTT LABORATORIES · Health Care
SATURNA CAPITAL CORP reported holding 387,396 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$38.3M, representing 0.45% of its reported portfolio and ranking #39 among its reported holdings. SATURNA CAPITAL CORP has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How SATURNA CAPITAL CORP's ABT position evolved
SATURNA CAPITAL CORP first disclosed a stake in ABT in Q3 2023 at 432,691 shares (US$41.9M). The position peaked in Q2 2025 at 392,395 shares, worth US$53.4M. Across 13 filings, SATURNA CAPITAL CORP increased the stake 0 time(s), trimmed it 5 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 387,396 shares valued at US$38.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 432.69K | $41.91M | New |
| Q4 2023 | 426.92K | $46.99M | Reduce |
| Q1 2024 | 424.10K | $48.20M | Reduce |
| Q2 2024 | 407.10K | $42.30M | Reduce |
| Q3 2024 | 394.07K | $44.93M | Reduce |
| Q4 2024 | 394.19K | $44.59M | Hold |
| Q1 2025 | 393.32K | $52.17M | Hold |
| Q2 2025 | 392.39K | $53.37M | Hold |
| Q3 2025 | 392.30K | $52.54M | Hold |
| Q4 2025 | 391.86K | $49.10M | Hold |
| Q1 2026 | 391.93K | $40.24M | Hold |
| Q2 2026 | 388.94K | $35.29M | Reduce |
| Q3 2026 | 387.40K | $38.29M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.65B), Charles Schwab Investment Management (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 57.16M sh · $5.65B · Q3 2026
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 44.98M sh · $4.45B · Q3 2026
- Capital International Investors 35.46M sh · $3.51B · Q3 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Franklin Resources 20.44M sh · $2.36B · Q3 2026
- Deutsche Bank AG 17.69M sh · $1.75B · Q3 2026
- MFS Investment Management 14.93M sh · $1.48B · Q3 2026
More on SATURNA CAPITAL CORP
FAQ
How long has SATURNA CAPITAL CORP held ABT?
SATURNA CAPITAL CORP has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is SATURNA CAPITAL CORP's current position in ABT?
As of Q3 2026, SATURNA CAPITAL CORP holds 387.40K shares of ABT (ABBOTT LABORATORIES), valued at $38.29M, representing 0.45% of its reported portfolio and ranking #39.
Has SATURNA CAPITAL CORP been buying or selling ABT?
In the latest 13F filing (Q3 2026), SATURNA CAPITAL CORP held unchanged its position in ABT. The position peaked in Q2 2025 at 392.39K shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, Charles Schwab Investment Management, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.